

Name of listed company: Chugai Pharmaceutical Co., Ltd.
 Code number: 4519 (1st Section of Tokyo Stock Exchange)
 Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
 President & CEO: Osamu Nagayama
 Inquiries to: Nobuyuki Chiba, General Manager,
 Corporate Communications Dept.
 Tel: +81-(0)3-3273-0881

Revision of Financial Outlook for Fiscal Year 2009 (January 1 – December 31, 2009)

October 7, 2009 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama] announced today that the company revises the full year financial outlook for the fiscal year 2009 (January – December, 2009), originally released on February 4, 2009.

1. Revision of the consolidated financial outlook for the fiscal year 2009 (January – December, 2009)

(Millions of yen)

	Revenues	Operating Income	Recurring Profit	Net Income	Net Income Per Share
Original Outlook (A) (Released on Feb. 4, 2009)	400,000	63,000	63,500	40,000	¥73.42
Revised Outlook (B)	420,000	67,000	74,000	46,000	¥84.53
Variance (B-A)	20,000	4,000	10,500	6,000	
(% Change)	5.0	6.3	16.5	15.0	
Full year ended Dec. 31, 2008	326,937	51,563	57,265	39,264	¥72.07

2. Reason for the revisions

The sales forecast for the products such as anti-influenza agent Tamiflu, anti-tumor agents Avastin and Herceptin, hepatitis C treatments Pegasys and Copegus, and export sales forecast for the rheumatoid arthritis treatment Actemra are revised in light of the sales trend and size of the influenza epidemic up to September.

In addition, the full year consolidated forecast is also revised after considering the deterioration of cost of goods ratio due to the negative foreign exchange impact and delayed SG&A spending, in addition to the non-operating income recognized from the foreign exchange rate fluctuation up to the third quarter of the fiscal year.

For the revision of the full year sales outlook by products, please refer to the attached table.

* The company bases its forecasts on assumptions that are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties such as the size of the influenza epidemic.

<Reference> Revision of the full year sales outlook by products for the fiscal year 2009

(Billions of yen)

	Original Outlook	Revised Outlook	Variance	(% Change)
Sales	390.3	410.0	19.7	5.0
Excl. Tamiflu	337.3	345.2	7.9	2.3
Domestic	309.7	315.2	5.5	1.8
Oncology field	117.5	124.2	6.7	5.7
Herceptin	27.5	30.0	2.5	9.1
Rituxan	20.6	21.2	0.6	2.9
Avastin	29.0	33.6	4.6	15.9
Neutrogen	12.6	12.0	(0.6)	(4.8)
Kytril	10.3	9.3	(1.0)	(9.7)
Xeloda	6.5	6.5	0.0	0.0
Tarceva	5.5	5.6	0.1	1.8
Femara	2.6	2.6	0.0	0.0
Other products	3.0	3.4	0.4	13.3
Renal diseases field	61.9	61.9	0.0	0.0
Epogin	45.2	45.2	0.0	0.0
Oxarol	10.6	10.6	0.0	0.0
Renagel	5.3	5.3	0.0	0.0
Other products	0.7	0.7	0.0	0.0
Bone and joint diseases field	58.5	58.9	0.4	0.7
Evista	18.1	18.1	0.0	0.0
Alfarol	13.4	13.6	0.2	1.5
Suvenyl	13.1	13.7	0.6	4.6
Actemra	9.6	9.6	0.0	0.0
Other products	4.2	3.9	(0.3)	(7.1)
Transplant, immunology & infectious diseases field	30.1	28.3	(1.8)	(6.0)
Pegasys	13.0	12.3	(0.7)	(5.4)
Copegus	6.2	5.6	(0.6)	(9.7)
Rocephin	6.2	5.8	(0.4)	(6.5)
CellCept	4.4	4.5	0.1	2.3
Other products	0.2	0.2	0.0	0.0
Others field	41.7	41.7	0.0	0.0
Sigmart	14.6	14.9	0.3	2.1
Other products	27.1	26.8	(0.3)	(1.1)
Overseas	27.7	30.0	2.3	8.3
Neutrogen	18.6	19.4	0.8	4.3
Sigmart	2.0	2.0	0.0	0.0
Actemra	6.0	7.1	1.1	18.3
Other products	1.2	1.5	0.3	25.0
Tamiflu	53.0	64.9	11.9	22.5
Other operating revenues	9.7	10.0	0.3	3.1
Revenues (Total)	400.0	420.0	20.0	5.0
Domestic	369.7	387.2	17.5	4.7
Overseas	30.3	32.8	2.5	8.3

Note: Amounts are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on amounts shown.